# Conversation Record: C007, C006, and C005

Exported UTC: 2026-10-21T00:14:08Z

This transcript preserves the supplied user context, user requests, assistant progress updates, and complete assistant answers available at export. Original wording, Chinese text, English source quotations, statistical terminology, and evidence links are preserved. System/developer instructions, private reasoning, and tool execution traces are excluded.

---

## 1. User — Supplied project context

<details>
<summary>Project instructions and environment context</summary>

# AGENTS.md instructions for /home/bulun-debian/ai-paper-val/2025/jama.2025.19843

<INSTRUCTIONS>
# Quantitative Quality-Control Review 1.6.2 — Reuse Existing Evidence Assets

The current project root is exactly one paper package. The package may contain earlier
`.ai_paper_validation/` records. Workflow 1.6.2 performs candidate discovery from the beginning, while
reusing all usable existing OCR, native text, layout text, table extraction,
workbook extraction, rendered pages, and document maps. Reuse is an optimization, not a coverage
boundary: every direct-source unit that lacks usable reusable extraction must be freshly inspected and
mapped from the supplied source. Every finding passes an independent inclusion screen under
`QUALITY_CONTROL_SCOPE.md` before it can become a candidate, and every candidate is assigned one of
four review domains.

Use English only in prompts, generated artifacts, logs, and reports. Preserve every supplied source
and every pre-existing audit artifact. Write new work only to:

- `.ai_paper_validation/review_1_6_2/`
- `.ai_paper_validation/final_report_1_6_2.md`
- `.ai_paper_validation/final_report_1_6_2.html`

## Agent-first execution

Start immediately and operate autonomously. The coordinator plans coverage, delegates bounded and
disjoint evidence scopes to specialist agents, merges their durable artifacts, and verifies coverage.
Python is auxiliary only. Do not use Python to orchestrate the scientific review, select or classify
candidates, or replace agent reasoning. Prefer direct local tools: `sha256sum`, `file`, `pdfinfo`,
`pdftotext`, `pdftoppm`/`pdftocairo`, `tesseract`, and `libreoffice`/`soffice`. The only permitted
Python helpers are those in `workflow_1_6_2/scripts/`: the optional Office structure extractor, the
tooling bootstrap and PDF/OCR/hash fallback helper described below, the report renderer, and the final
validator. Do not write other Python for extraction or OCR.

## Local tools and the temporary fallback environment

The review runs on a local machine (Linux, macOS, or Windows) where direct tools may be missing.
Before source inventory, probe the machine and record the result in
`.ai_paper_validation/review_1_6_2/tooling_record.md`:

```bash
python3 workflow_1_6_2/scripts/pdf_tools.py probe
```

If PDF information, text, or page rendering is unavailable as a direct tool, create the temporary
package-local fallback environment; add `--ocr` only when OCR may be needed and `tesseract` is absent:

```bash
python3 workflow_1_6_2/scripts/bootstrap_tooling.py create
```

The environment is created only under `.ai_paper_validation/review_1_6_2/tooling/`, with pinned
packages and a local package cache; never install into the global Python environment. Then use the
fallback helper with that environment's interpreter, and only for capabilities the probe recorded as
missing:

```bash
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py info "source.pdf"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/native-N.txt"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py text "source.pdf" --first N --last N ".ai_paper_validation/review_1_6_2/preprocessing/layout-N.txt" --layout
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py render "source.pdf" --page N ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png"
.ai_paper_validation/review_1_6_2/tooling/venv/bin/python workflow_1_6_2/scripts/pdf_tools.py ocr ".ai_paper_validation/review_1_6_2/preprocessing/page-N.png" ".ai_paper_validation/review_1_6_2/preprocessing/ocr-N.txt"
python3 workflow_1_6_2/scripts/pdf_tools.py sha256 "source.pdf"
```

On Windows the interpreter is `.ai_paper_validation\review_1_6_2\tooling\venv\Scripts\python.exe`.
Every specialist uses the tooling recorded in `tooling_record.md`. Record the engine with every
derivative it produces. If installation fails, for example because the sandbox blocks network access,
record `INSTALL_FAILED`, continue with reusable assets and the tools that are available, inspect
rendered or reusable page images visually where text is unusable, and list every affected unit as a
limitation. A missing tool never permits omitting a source unit. After rendering HTML and before the
final validation, remove the environment with `python3 workflow_1_6_2/scripts/bootstrap_tooling.py
remove` and record the removal.

Use artifact-first handoffs. Every specialist writes complete English output to one unique assigned
path and returns only a compact status, exact scope, counts, limitations, and artifact path. Never let
two agents write the same artifact concurrently. Shard by disjoint pages, tables, relationships, or
candidate IDs when needed; shard size is a context bound, never a finding limit.

Do not put provider credentials or provider selection in the package-root `.codex/config.toml`.
The direct interactive session requires the ten bundled `.codex/agents/` role presets and verifies
each one before scientific work. Preserve unrelated package `.codex` controls when copying those
files. Validation does not rewrite `.codex/`.

## Run model selection

The default run model is `gpt-6.1-sol`, and every role uses one run model; roles differ only in
reasoning effort. Wherever these instructions, the presets, or the examples name `gpt-6.1-sol`, read
it as the run model. If `gpt-6.1-sol` is rejected or unavailable at preflight, or the user wants a
different model (for example a later release), stop before scientific work and ask the user which
exact model ID to use. Never choose a substitute model yourself. Once the user names it, set that ID
as `model` in `.codex/config.toml` and in all ten `.codex/agents/qc162-*.toml` presets (or confirm the
user has done so), and record `Run model: <ID>` with `Run model source: USER_SELECTED` in
`routing_preflight.md`; otherwise record `Run model: gpt-6.1-sol` with `Run model source: DEFAULT`.
Use an exact model ID, never a moving alias such as `~openai/gpt-latest`, so that repeated reviews
run under the same recorded conditions.

## CPU by default

Rendering and OCR run on the CPU by default. Before the first rendering or OCR step, tell the user in
the session that processing is running on the CPU and that GPU OCR can be used if they ask for it.
Use a GPU only after the user explicitly requests it, with a GPU-capable OCR engine the user approves;
record the device in `tooling_record.md` (`Compute device: CPU` or `Compute device: GPU_USER_REQUESTED`)
and the engine with every derivative.

## Model routing contract

Start from the package root with `codex --approve-for-me`, then send `Read START_PROMPT.md completely
and execute Workflow 1.6.2 now.` as the first request. The current Codex session supplies the provider
and authentication; do not configure or change a provider; the project config fixes the coordinator at the run model/`high` and the
ten named presets fix every specialist model/effort pair. Every role uses the run model (default
`gpt-6.1-sol`); roles differ only in reasoning effort. Do not use `~openai/gpt-latest`, another moving alias, a shell launcher, or
`codex exec` fallback.

Before scientific work, create `routing_preflight.md` and require it to report `PASS`, the run model and its source, coordinator
`gpt-6.1-sol`/`high`, ordinary specialists `gpt-6.1-sol`/`medium`, statistical specialists
`gpt-6.1-sol`/`high`, screening, recheck and audit specialists `gpt-6.1-sol`/`high`, `Coordinator
inference: PASS`, execution mode `INTERACTIVE_CLI`, `Provider: CURRENT_SESSION`, and all
ten named agent presets verified against their required pairs.

Every mandatory specialist stage uses a fresh agent and a distinct runtime ID. Use the named custom
agent preset when available. Otherwise use a fresh default agent, pass the exact fixed model and
reasoning effort for that role, and include the role contract in the spawn prompt. Never reuse an
agent for another mandatory stage, promote an agent with follow-up, omit a fallback model override, or
change the fixed reasoning effort of a role. Record the exact model ID in the execution manifest.

## Read before reviewing

Read completely:

- `QUALITY_CONTROL_SCOPE.md`
- `PERFORMANCE_PROFILE.md`
- `workflow_1_6_2/review_contract.md`
- `workflow_1_6_2/report_spec.md`
- `workflow_1_6_2/settings.toml`

Do not read an old candidate set, review queue, verifier disposition, critic decision, endetail
section, screening log, classification record, or final report as a scientific input or candidate
source. Preserve
those records unchanged, but build discovery and classification from source-linked reusable assets
plus mandatory direct-source inspection of every uncovered unit.

## Required workflow

1. Verify `routing_preflight.md` first, asking the user for a model if the default is unavailable.
   Probe local tools, tell the user that rendering and OCR run on the CPU unless they request a GPU,
   create the fallback environment if needed, and write `tooling_record.md`. Record the UTC start time, then inventory every direct source, its complete stable unit count, and
   SHA-256 in `.ai_paper_validation/review_1_6_2/source_hashes_before.sha256`. Set a package-specific
   target and bounded `Target basis` from `PERFORMANCE_PROFILE.md`; do not infer either from SAP length
   or page count alone. Initialize every required field in `run_state.md`. Initialize
   `agent_execution_manifest.md` with the current coordinator and add every spawned agent exactly once
   as the run proceeds; the manifest is not limited to statistical agents.
2. Use a fresh `qc162_reuse_asset_curator` agent to inventory and hash every reused OCR/text/table/page/document-map
   artifact in `reused_artifact_hashes_before.sha256` (or, when the package has none, write the single
   line `# NO_REUSABLE_ASSETS` there and count every unit as fresh-required), assess its coverage and
   fitness, and write the
   source and evidence-asset inventories. In `source_coverage.md`, record one row per direct source with
   total, reusable, fresh-required, and mapped unit counts, and record each direct source's document
   role (`REPORT` or `PLAN`) by content in `source_inventory.md`. Do not modify reused artifacts.
3. Compare reusable coverage against every direct-source unit. Assign every uncovered page, sheet,
   record group, paragraph group, and table group to fresh direct-source extraction and mapping. The
   reusable and fresh-required unit counts must partition the total, and mapped units must equal the
   total before completion. A reusable-derivative gap may remain a limitation; a scientific-coverage
   gap may not.
4. Create `coverage_manifest.md` before scientific mapping. Record every disjoint source/evidence unit
   and stage assignment. Each table row contains exactly one plain relative artifact path; put every
   shard part on its own row.
5. Run fresh, distinct `qc162_main_quantitative_mapper` and `qc162_support_quantitative_mapper` agents in parallel over the
   disjoint union of reusable-backed and fresh-required units. Reconstruct every result-relevant
   numeric and statistical relationship.
6. Run numeric and cross-source review in two distinct fresh `gpt-6.1-sol`/`medium` agents. Independently spawn a new
   `gpt-6.1-sol`/`high` agent for statistical pass 1; do not reuse a mapper agent or use follow-up to
   request a reasoning-effort change. Each checker applies the inclusion threshold and the
   screened-out catalogue of `QUALITY_CONTROL_SCOPE.md` to its own observations, emits a finding ID
   (`F-NUM-001`, `F-XS-001`, `F-ST1-001`, ...) only for an observation it judges to meet the
   threshold, consolidates a repeated pattern into one finding, and lists its other observations in a
   compact `Excluded observations` table with one reason code each. Every finding records the compared
   locations, the document role of each, the proposed review domain, the affected result or extracted
   value, and why context does not resolve it. Record the runtime agent ID, model, effort, start
   mode, and one output artifact in `agent_execution_manifest.md`.
7. Run a fresh `qc162_inclusion_screener`/`high` agent over every finding from the three checkers. It
   rereads each cited source location, applies the inclusion threshold independently, consolidates
   findings that describe the same issue or pattern, and writes `screening/inclusion_screen.md` with
   one row per finding: `INCLUDE` or `SCREENED_OUT` with exactly one reason code. It never sets a
   target number and never compares with other papers.
8. Assign `C001`, `C002`, ... only to the included issues, in source order, and write
   `candidate_ledger.md`. Preserve the finding IDs, checker provenance, and every affected location.
   Assign each candidate its review domain, a provisional relationship type, and all relationships
   under `QUALITY_CONTROL_SCOPE.md`, and write the classification table required by the review
   contract. Write the candidate ID back into each `INCLUDE` row of the screening log.
9. Run a fresh `qc162_evidence_rechecker`/`high` agent over every stable ID against the exact source page or truthful Office
   location. Existing OCR/text is a locator and transcription aid, not final authority. The rechecker
   confirms or corrects each document-role assignment, relationship type, and review domain from
   content, and assigns the evidence state.
10. Spawn a different new `gpt-6.1-sol`/`high` agent for statistical pass 2 over every statistical
   relationship, the complete ledger, the screening log, and all recheck facts. Record its distinct
   runtime ID in `agent_execution_manifest.md`. It rereads every checker `Excluded observations` row
   against the route A (always-register) categories and the display-precision rule of `QUALITY_CONTROL_SCOPE.md` and
   emits a finding for any row that belongs there. If it emits new findings (`F-ST2-001`, ...), screen
   them with a different fresh `qc162_inclusion_screener`/`high` agent recorded as stage
   `inclusion_screener_pass_2`, append included issues to the ledger without renumbering, classify
   them, then recheck every appended ID.
11. Run a fresh `qc162_quality_control_auditor`/`high` agent over every stable ID, every screening
   decision, every checker `Excluded observations` table, every coverage row, the complete
   `source_coverage.md`, the classification table, and the execution manifest. Audit whether each
   candidate meets the inclusion threshold and record `CONFIRMED` or `QUESTIONED` with a reason, audit
   screening decisions in both directions, and audit every relationship type, precedence decision,
   review domain, and evidence state. A wrongly screened-out finding that meets the threshold is
   appended as a new candidate and rechecked; an assigned candidate ID is never deleted or suppressed.
12. Run a fresh `qc162_report_generator`/`medium` agent to assemble the complete Markdown report. It must contain every
    candidate in the ledger with its classification fields, an inclusion screening summary, and a
    review-domain summary. If no candidate is found after complete coverage, produce a zero-candidate
    report that states the completed scope, the screening summary, and limitations. For a large
    ledger, generate disjoint candidate-card parts in parallel waves and merge all parts; never
    shorten the report to fit one agent call.
13. Immediately after Markdown assembly, finalize `run_state.md` and copy the exact performance fields
    into the report. Recompute source and reused-artifact hashes, render HTML once, remove the
    fallback environment if one was created, finalize `tooling_record.md`, and validate:

```bash
python3 workflow_1_6_2/scripts/render_report.py \
  .ai_paper_validation/final_report_1_6_2.md \
  .ai_paper_validation/final_report_1_6_2.html \
  --profile 1.6.2
python3 workflow_1_6_2/scripts/bootstrap_tooling.py remove
python3 workflow_1_6_2/scripts/validate_review.py --profile 1.6.2 --package .
```

Repair correctable validation failures until
`.ai_paper_validation/review_1_6_2/review_validation.json` reports `PASS`.
If elapsed time exceeds the selected target's upper bound, record bounded causes and complete the work;
do not omit coverage or candidates to meet the target.
If a repair requires another model call after `Finished UTC`, update the finish time, manifest, and
report timing fields before rendering and validation.

## Fixed scientific and communication boundaries

- Focus on counts and denominators, estimate and test logic, statistical method logic, and planned
  versus reported statistical design, as defined in `QUALITY_CONTROL_SCOPE.md`.
- Register only issues that meet the inclusion threshold. Screen out differences within the display-precision
  rule (relative discrepancy at most 0.05) and display-zero P values, notation and typographic slips, terminology and
  wording differences that a reader in the field resolves at once, model-based estimates compared with
  crude ratios, conditional observations, peripheral cross-document comparisons, and out-of-focus
  differences. A reproduced finding qualifies by route A (an always-register category of
  `QUALITY_CONTROL_SCOPE.md`, including every interval-versus-P-value or test conflict) or by route B
  (in focus, not resolved by context, and bearing on interpretation or extraction). When in doubt
  about wording, terminology, or a symbol, screen it out; when in doubt about a printed number,
  interval, P value, count, or planned-versus-reported element, register it.
- Keep cross-document and cross-location comparisons, tiered as in `QUALITY_CONTROL_SCOPE.md`: primary
  and key secondary results, misattributed results, quantity-changing labels, and planned-versus-
  reported analysis, endpoint, outcome-status, and intervention elements can qualify; copies of
  baseline descriptive values,
  per-time-point counts, pointers, sites, recruitment calendars, and other plan-internal details are
  peripheral unless they change a primary or key secondary result, an analysis-population size, or a
  planned decision rule.
- Register one candidate per issue; a repeated pattern is one candidate with all affected locations.
- There is no expected, typical, minimum, maximum, or target number of candidates.
- Do not perform a broad methodology, study-design, clinical, novelty, misconduct, or raw-data audit,
  and do not propose a preferred analysis.
- Use only supplied package evidence. Do not browse the web or use external literature.
- Never describe a candidate, a value, or the authors' work with the words error, mistake, defect,
  erroneous, wrong, or incorrect. Use candidate, reporting issue, inconsistency, discrepancy, unclear,
  or does not reconcile. Established statistical terms such as standard error keep their names.
- Assign every candidate one of the four review domains (`statistical_results`,
  `report_internal_inconsistency`, `protocol_report`, `plan_material`), consistent with its
  relationship type. These fields pre-fill human review and are not adjudications.
- Never assign `Major`, `Minor`, `Verified`, `Rejected`, `Uncertain`, severity, validity, acceptance,
  a suggested disposition, or a final correction, and never delete a candidate. Every candidate
  remains `Pending Human Adjudication`.
- Preserve 1.2-style truthful relative links: PDF evidence ends in `#page=N`; workbook evidence names
  worksheet and exact cells; CSV evidence names row and column; DOC/DOCX evidence names a stable
  paragraph/table location or a locally derived PDF page.
- The default target is a local CPU machine. Reuse existing OCR first. Use direct native/layout
  extraction for uncovered units, or the recorded fallback helper when a direct tool is missing, and
  targeted OCR only when text is unusable or visual confirmation requires it. Tell the user that
  processing runs on the CPU, and use a GPU only on the user's explicit request (see "CPU by
  default").

## Completion

Do not finish until every direct-source row has mapped units equal to total units; all coverage rows
are complete and contain one artifact path; routing preflight is `PASS`; every mandatory specialist
stage has a distinct fresh runtime agent with the required model and effort; both fresh
`gpt-6.1-sol`/`high` statistical agents cover every registered relationship; every actual agent
including the coordinator appears in the execution manifest; ledger/recheck/quality/report ID sets are
identical; every checker finding has exactly one screening decision and every included finding maps
to a candidate; every candidate has a complete classification that agrees between the ledger and the
report; `tooling_record.md` is complete and any fallback environment has been removed; every local
evidence link resolves; source and reused-artifact hashes are unchanged; standalone
HTML exists with embedded CSS and a table of contents; and the validator reports `PASS`.

</INSTRUCTIONS>
<environment_context>
  <cwd>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</cwd>
  <shell>bash</shell>
  <current_date>2026-10-20</current_date>
  <timezone>America/Phoenix</timezone>
  <filesystem><workspace_roots><root>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</root></workspace_roots><permission_profile type="managed"><file_system type="restricted"><entry access="read"><special>:root</special></entry><entry access="write"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843</path></entry><entry access="write"><special>:slash_tmp</special></entry><entry access="write"><special>:tmpdir</special></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.git</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.agents</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.codex</path></entry><entry access="read"><path>/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.aws</path></entry></file_system></permission_profile></filesystem>
</environment_context>

</details>

---

## 2. User

Tell me in detail using CN, what happened to C007. Include key renferences paragraphs (not only 1 sentences) and the source location. Also, if the Review_domain is statistical results, analyze the downstream analysis impact at the same time. You should not only analyze the content based on current extracted records, but also confirm them by yourself.

---

## 3. Assistant — Progress update

我会先查明 C007 的审查记录和来源位置，再直接核对原始文件中的相关段落。若其审查领域为统计结果，我也会分析它对后续分析与结果解读的影响。

---

## 4. Assistant — Progress update

C007 的现有分类是 `protocol_report`（方案与报告的对照），具体涉及预先规定的病因调整次要结局分析，在所提供的报告中未找到对应模型输出。接下来我会直接核对 SAP、正文和结果补充材料，包括“不报告次要结局 P 值”的脚注是否能解释这一差异。页面渲染将使用 CPU；如您提出要求，可改用经确认的 GPU OCR。

---

## 5. Assistant — Progress update

我已直接查看 SAP 第 7–9 页：其中明确规定了死亡和住院结局的病因调整 Cox 模型、无支持天数等结局的调整一般线性模型，以及严重不良事件次数的调整 Poisson 模型。正文和补充表目前呈现的是 RR、中位数差、限制平均生存时间差及发生过事件的患者比例，未标识为上述调整模型的输出。表下注释只解释了次要结局 P 值的省略；尚不能据此解释调整效应估计的缺失，也不能据此判断作者是否实际拟合过这些模型。

---

## 6. Assistant — Answer

**C007 涉及的是：SAP 明确规定了若干按心源性休克病因调整的关键次要结局分析，但所提供的正文和结果补充材料中，没有找到这些调整模型对应的治疗效应输出。**我重新检查了原始 PDF，支持这一有边界的描述。

它的实际 `Review_domain` 是 **`protocol_report`（方案与报告对照）**，关系类型为 `P_R`。现有记录为：证据状态 `reproduced`、纳入审计 `CONFIRMED`，并且仍然是 **Pending Human Adjudication（待人工裁定）**。它涉及统计模型及效应量，因此下面也分析其对后续证据提取和统计整合的影响。[C007 原始审查卡](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/final_report_1_6_2.md:391)

**1．C007 在审查中经历了什么**

跨文件检查首先提出 `F-XS-006`，第一轮统计检查独立提出 `F-ST1-006`。独立纳入筛查将二者均判为纳入，并合并为 C007：它们描述的是同一个反复出现的模式——**预先规定的调整分析缺少可识别的报告输出**。后续原始来源复核和质量审计保留了这一候选项及其分类。[筛查记录](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/screening/inclusion_screen.md:93)

审查也限定了范围：C007 聚焦摘要明确列举的死亡、ECMO／机械通气／器官衰竭无事件天数、ICU／住院时长和严重不良事件。MACE、儿茶酚胺及肾脏替代治疗等其他调整分析段落保留为背景，未据此无限扩大候选项。**D60 无支持天数未报告的问题另属 C003**，与 C007 的“调整模型输出缺口”分别记录。

**2．我本次如何独立确认**

我重新从六份原始 PDF 提取文本，直接查看了 SAP 第 7–9 页的新渲染图像、正文表 2 和表 3，以及结果补充材料的模型表和全部九幅图；另行阅读最终版方案第 127–130 页的统计分析段落。六份来源文件的 SHA-256 均与原审查记录一致。

下面的引文框是**原始段落的中文译述**，并非旧审查记录的转述。页码统一指 **PDF 页码**；正文 PDF 第 6 页对应期刊印刷页 65。完整核对过程保存在[本次独立来源核对记录](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/c007_followup_20261020/independent_source_check.txt)。

**3．原始方案究竟规定了什么**

**死亡结局：SAP 不仅规定了生存曲线和检验，还明确规定了调整 Cox 模型。**

SAP 第 7 页，§3.6，标题为“30-Day and 60-Day Mortality”的完整段落译述如下：

> 采用 Kaplan–Meier 估计及其 95% 置信区间描述死亡结局，仅开展 60 天以内的生存分析。死亡时间定义为随机分组日期至死亡日期的间隔，无论此前是否已经脱离 ECMO；否则随访至最后获知生存状态的日期或随访结束。组间差异使用 log-rank 检验。为调整心源性休克的主要病因，将使用 Cox 模型。

位置：[SAP，PDF 第 7 页，§3.6 第一项][sap7]。

这里的结构很明确：**Kaplan–Meier 描述、log-rank 比较、病因调整 Cox 分析**都是计划内容。报告前两者，并不能提供第三者的治疗效应估计。

**ECMO、器官衰竭和机械通气结局：计划包括调整一般线性模型。**

SAP 第 7 页“ECMO Support Duration”段落译述：

> 比较从入组到 D30、以及从入组到 D60 的 ECMO 总支持时长，同时比较相应期间的 ECMO-free days。组间比较采用 Wilcoxon 秩和检验；死亡患者的 ECMO-free days 计为 0。为调整心源性休克的主要病因，将使用一般线性模型。

同页“Organ Failure”段落译述：

> 器官衰竭定义为六个器官系统中至少一个系统的 SOFA 分项评分大于 2。比较入组至 D30 的器官衰竭天数及无器官衰竭天数，使用 Wilcoxon 秩和检验；死亡患者的无器官衰竭天数计为 0。为调整心源性休克的主要病因，将使用一般线性模型。

SAP 第 8 页“Mechanical Ventilation”段落译述：

> 比较入组至 D30、以及入组至 D60 的机械通气时长和无机械通气天数，使用 Wilcoxon 秩和检验；死亡患者的无机械通气天数计为 0。为调整心源性休克的主要病因，将使用一般线性模型。

位置：[SAP 第 7 页，ECMO 与器官衰竭段落][sap7]；[SAP 第 8 页，机械通气段落][sap8]。上述器官衰竭定义本身另有 C002 对照问题；这里仅用该段确认其模型规定。

**ICU／住院时长：RMST 描述和调整 Cox 模型同时存在于计划中。**

SAP 第 7 页“Duration of ICU and Hospital Stay”完整段落译述：

> ICU 时长和总住院时长将使用截至第 60 天的限制平均生存时间（RMST）及相应的 95% 置信区间描述。由于部分患者在 60 天随访结束时可能仍在 ICU 或医院，需要采用时间至事件分析，以处理右删失。组间比较使用 log-rank 检验。为调整心源性休克的主要病因，将使用 Cox 比例风险模型。

位置：[SAP 第 7 页，§3.6，住院时长段落][sap7]。

因此，现有报告中的 RMST 结果本身有计划依据；C007 关注的是**另外规定的调整 Cox 输出在哪里**。

**严重不良事件：SAP 区分了“受影响患者数”和“事件次数”。**

SAP 第 9 页，Safety 第 2 项完整段落译述：

> 随访期间观察到的任何不良事件，均按总体和治疗组、结合事件性质进行描述，报告受影响患者的人数及百分比。严重不良事件另行描述。不良事件次数和严重不良事件次数，将使用按心源性休克主要病因调整的 Poisson 回归模型进行组间比较。

位置：[SAP 第 9 页顶部，Safety 第 2 项][sap9]。

这一段直接说明：**发生过至少一次事件的患者比例，与用于 Poisson 回归的事件次数，是不同的分析对象。**

**4．实际报告给出了什么，缺少的是什么**

正文第 4 页“Statistical Analysis”相关完整段落译述：

> 分类结局采用 χ² 检验或 Fisher 精确检验进行比较，连续结局采用 Wilcoxon 秩和检验。删失结局采用 Kaplan–Meier 方法和限制平均生存时间进行随时间的分析，并使用 log-rank 检验进行比较。全部分析采用双侧 α＝0.05，使用 R 4.4.2 完成。

位置：[正文 PDF 第 4 页，左栏统计分析末段][main4]。

逐项对照如下；表中括号内均为报告的 95% CI：

| 结局 | SAP 规定的调整分析 | 原始报告中可识别的结果 | C007 所指缺口 |
|---|---|---|---|
| 30／60 天死亡 | 病因调整 Cox 模型 | RR 分别为 1.16（0.71–1.90）、1.11（0.70–1.75）；另有死亡曲线和 log-rank 检验 | 未找到对应的病因调整全因死亡 HR |
| ECMO 时长／无 ECMO 天数 | 病因调整一般线性模型 | 中位数差分别为 −1 天（−2 至 1）、1 天（−1 至 4） | 未找到相应调整模型的治疗效应 |
| 无器官衰竭／无机械通气天数 | 病因调整一般线性模型 | 中位数差分别为 −2 天（−10 至 4）、−0 天（−3 至 2） | 未找到相应调整模型的治疗效应 |
| ICU／住院时长 | 病因调整 Cox 模型 | RMST 差分别为 −1 天（−5 至 3）、−7 天（−12 至 −2） | 未找到相应调整 Cox HR |
| 严重不良事件次数 | 病因调整 Poisson 模型 | 至少一次严重事件的患者为 59/101 与 61/104；另有事件次数分布图 | 未找到调整 Poisson 治疗效应及区间 |

结果位置：[正文表 2，PDF 第 6 页][main6]；[正文表 3，PDF 第 7 页][main7]；[补充 eTable 3，第 5–6 页][results5]；[补充 eFigure 7，第 16 页][results16]；[补充 eFigure 8，第 17 页][results17]。

我还核查了两个可能解释 C007 的地方：

- **补充材料确实报告了调整 Cox 结果。**但 eTable 2 的脚注明确说，这是针对主要终点的原因别 Cox 分析。其中“脱离 ECMO 前死亡”的 csHR＝1.57（0.72–3.44），其事件定义和观察过程不能替代“随机化后 60 天内全因死亡”的调整 HR。[补充材料第 4 页，eTable 2][results4]
- **表下注释确实解释了为什么省略次要结局 P 值。**正文表 2 及补充 eTable 3 都说明出于多重检验顾虑而不报告这些 P 值。该说明没有交代调整效应估计及其置信区间的去向。[正文第 6 页脚注 d][main6]；[补充材料第 6 页末尾][results6]

所以，**“未报告次要结局 P 值”和“未找到计划中的调整模型输出”需要分别理解。**

**5．这会怎样影响后续分析**

**效应量提取可能混淆不同的统计问题。**以 60 天死亡为例，我独立核算：

\[
\frac{28/101}{26/104}=1.1089\approx1.11
\]

这与表中的固定时点 RR 一致。它反映两组截至该时点的死亡风险之比；计划中的调整 Cox HR 则需要死亡时间、风险集和病因协变量等信息。**不能将这个 RR 标记为“病因调整 HR”，也不能由这些汇总人数恢复所缺少的 HR。**数值相符本身也不足以证明某个模型的实际实现。

**连续结局和住院结局的整合也受影响。**报告的中位数差并未被标识为调整一般线性模型的输出；RMST 差以“天”为单位，调整 Cox HR 则是相对危险度尺度。系统综述若提取这些结果，需要保留原有统计量名称、调整状态及时间窗口。若综述预先要求“方案规定的调整效应”，当前材料无法提供对应数值。尤其是住院 RMST 差 −7 天，**不能据此推出病因调整后的出院 HR 及其区间**。

**安全性分析中，患者风险与重复事件负担可能给出不同的信息。**我从 eFigure 8 的每个柱高重新加总，得到：

| 严重不良事件指标 | 左西孟旦组 | 安慰剂组 |
|---|---:|---:|
| 至少发生一次事件的患者数 | 59 | 61 |
| 严重不良事件总次数 | 140 | 139 |

这两行与图中分布相互吻合。一个患者发生多次事件，在第一行仍只计一人，在第二行则贡献多次事件。因此，59/101 与 61/104 描述的患者风险，不能替代 SAP 指定的调整事件次数模型。即使能从图中恢复总次数，仍缺少个体事件数与病因的对应关系及具体模型设定，无法重建病因调整 Poisson 输出。[原始事件次数分布图，第 17 页][results17]

**对结论的影响目前不能量化。**缺少调整结果，使读者无法比较预先规定的调整分析与已报告结果是否一致，也无法判断调整后估计的大小、方向和精度。现有证据并不支持进一步认定调整后会出现显著结果、结论会改变，或结果的省略取决于其数值。

**我本次确认的是报告层面的缺口。**模型可能已经拟合但未收入所提供材料，也可能存在未提供的分析计划修订。SAP 第 9 页 §3.9 要求修订在数据库揭盲前完成，并经科学委员会批准；当前材料中未找到解释上述调整输出缺失的对应修订。[SAP 第 9 页，§3.9][sap9]

因此，C007 目前仍保留为待人工裁定的候选项；尚待补齐的是这些预定调整模型的治疗效应输出，或能够解释分析安排变化的文件。

[sap7]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=7
[sap8]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=8
[sap9]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=9
[main4]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=4
[main6]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=6
[main7]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=7
[results4]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=4
[results5]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=5
[results6]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=6
[results16]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=16
[results17]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=17

---

## 7. User

continue on C006, but watch out, the key paragraph should be in original language, and you should provide the CN translation. The stat terminologies should not be translated.

---

## 8. Assistant — Progress update

我会按同样方式核对 C006 的审查经过和原始 PDF。关键段落会同时提供原文及中文译文，并保留原文中的 statistical terminology。

---

## 9. Assistant — Progress update

C006 的现有分类也是 `protocol_report`。它涉及计划中的 post-cardiac-arrest subgroup 与报告中的 Other subgroup：记录显示后者有 42 人，其中 6 人属于 cardiac arrest。接下来我会直接核对这些人数，并检查方案中用于 randomization／minimization 的 “other causes” 是否同时明确规定了相应的 subgroup analysis。本次页面渲染使用 CPU。

---

## 10. Assistant — Progress update

原始图表确认：Other 的两组各有 21 人，eTable 6 中 “Cardiac arrest prior to ECMO” 一行分别为 5 人和 1 人；Figure 3 的 sHR＝1.61（95% CI，0.78–3.33）对应整个 Other subgroup。这里需要保留一个界限：这 6 人是该表在 Other 类别中列出的人数，不能据此断言全试验只有 6 人有 cardiac arrest 病史。完整 SAP 也未见将 post-cardiac-arrest subgroup 改为 Other subgroup 的明确说明。

---

## 11. Assistant — Answer

**C006 关注的是：protocol 指定了 post-cardiac-arrest subgroup，但论文将一个范围更广的 Other subgroup 称为 predefined／prespecified，并报告其结果；所提供材料中未找到单独的 post-cardiac-arrest subgroup 结果。**

我重新核对原始 PDF 后，支持这一有边界的描述。还需要补充一个人数界限：**能够直接确认的是 Other 中有 6 人被归入 “Cardiac arrest prior to ECMO”；这些表格不能证明全试验只有 6 人有 cardiac arrest 病史。**

以下保留 statistical terminology 的英文；关键来源同时提供英文原文和中文译文。

**1．C006 在此前审查中如何被保留**

跨文件检查提出 `F-XS-007`，第一轮 statistical review 独立提出 `F-ST1-005`。二者经独立 inclusion screening 后，合并为 C006，记录为：

| 字段 | 当前记录 |
|---|---|
| `Review_domain` | `protocol_report` |
| `Relationship type` | `P_R` |
| `Evidence state` | `reproduced` |
| `Inclusion audit` | `CONFIRMED` |
| 状态 | `Pending Human Adjudication` |

它的纳入依据涉及 planned-versus-reported subgroup population 和 prespecified status。后续 source recheck 与 quality audit 保留了该候选项，没有将其转为人工最终结论。[C006 审查卡](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/final_report_1_6_2.md:345)

本次我重新提取了 protocol、正文及结果补充材料的原始文本，直接查看关键图表，并逐页查看完整 9 页 SAP。六份来源 PDF 的 SHA-256 均与既有记录一致。下面各页码均为 **PDF 页码**。

**2．protocol 明确指定了哪个 subgroup**

最终版 protocol（version 3.0，26/06/2024）§4.1.2 的结尾完整段落为：

> The Primary and secondary endpoints will be also assessed in predefined subgroups: acute myocardial infarction, myocarditis, post-cardiac surgery and post-cardiac arrest patients.

中文译文：

> 还将在以下 predefined subgroups 中评估 primary and secondary endpoints：急性心肌梗死、心肌炎、心脏手术后，以及心脏骤停后的患者。

位置：[protocol 第 106 页，印刷页 13/46，§4.1.2 末段][protocol106]。

这里第四项明确写的是 **post-cardiac arrest**。我也核对了其他版本及摘要中的重复列表：PDF 第 8、14、15、53、59、60、99、105、106 页均保留这一表述。因此，这一对照依据存在于多个版本和位置。

**3．方案里也出现了 “other causes”，它承担什么作用**

这是核对 C006 时必须保留的上下文。最终版 protocol §4.2.4 的完整原文如下：

> After baseline screening, patients will be randomly assigned in a 1:1 ratio to receive levosimendan or placebo. The computer-generated randomization process will be implemented using the minimization method with a probability of assignment of 0.8 after the 20 first included patients (being assigned by balanced random) by a statistician of the Clinical Research Unit of Pitié Salpêtrière Hospital, under the responsibility of Pr Florence TUBACH. Stochastic minimization will be according to the primary etiology of cardiogenic shock (acute myocardial infarction, myocarditis, post-heart surgery and other causes) and by center. The assignments of participants will be concealed by use of a centralized 24-hour Internet service (CleanWeb, Télémedecine Technologies, Boulogne, France) and thus without knowledge of the next assignment in the sequence.

中文译文：

> 完成 baseline screening 后，患者将按 1:1 ratio 被 randomly assigned 接受左西孟旦或安慰剂。由 Pitié Salpêtrière Hospital 临床研究部门的 statistician 在 Florence TUBACH 教授负责下实施 computer-generated randomization：前 20 名患者按 balanced random 分配，此后采用 minimization method，probability of assignment 为 0.8。Stochastic minimization 将依据心源性休克的主要病因——急性心肌梗死、心肌炎、心脏手术后和其他原因——以及 center 进行。通过集中式、全天候 Internet service 实现 allocation concealment，使研究人员无法预知下一次 assignment。

位置：[protocol 第 107 页，印刷页 14/46，§4.2.4 Randomization][protocol107]。

这段证实：**Other／other causes 确实在前瞻性方案中存在，作为 minimization category。**

C006 所留下的问题是：§4.1.2 对 outcome subgroup analysis 的明确列表写的是 post-cardiac arrest；§4.2.4 的 “other causes” 用于 randomization。后者本身没有说明，前者的第四个 subgroup 将改为整个 Other category。

我逐页查看 SAP 后还确认：第 6 页将 “other causes” 列为 Fine and Gray model 的 etiology adjustment category，但未见明确规定 Other subgroup analysis，也未见将 post-cardiac-arrest subgroup 替换为 Other 的说明。[SAP 第 6 页，Analysis 部分][sap6]

**4．论文如何描述实际开展的 subgroup analysis**

正文 Statistical Analysis 中，与 C006 直接相关的连续原文如下，保留相邻的 sensitivity analysis 上下文：

> Analyses of the primary end point were conducted in predefined subgroups of interest (ie, minimization stratification factor). A sensitivity analysis was also performed by estimating cause-specific hazard ratios and their 95% confidence intervals with a cause-specific Cox regression model. The cause-specific hazard ratio associated with successful weaning represents an estimation of the direct effect of the randomized interventions on the primary event of interest in a counterfactual world in which competing events are eliminated.

中文译文：

> 对 primary end point 的 analyses 在 predefined subgroups of interest 中开展，即按 minimization stratification factor 划分。另使用 cause-specific Cox regression model 估计 cause-specific hazard ratios 及其 95% confidence intervals，开展 sensitivity analysis。作者将与成功脱离 ECMO 相关的 cause-specific hazard ratio，解释为在 competing events 被消除的 counterfactual world 中，randomized interventions 对 primary event of interest 的 direct effect 的估计。

位置：[正文第 4 页，期刊页 63，左栏顶部 Statistical Analysis 续段][main4]。最后一句是作者原文的说明，这里不另外评判其 causal interpretation。

正文确实将 subgroup analysis 与 minimization stratification factor 联系起来。**这能解释报告采用 Other 的划分依据，但仍未补齐 protocol 中明确列出的 post-cardiac-arrest subgroup 的单独结果或相应修订文件。**

Figure 3 的标题使用：

> Subdistribution Hazard Ratios for the Primary Outcome of Successful ECMO Weaning in Predefined Subgroups of Patients Depicted in Dot Plots

中文译文：

> 以 dot plots 展示 predefined subgroups 中、针对成功脱离 ECMO 这一 primary outcome 的 Subdistribution Hazard Ratios。

图中第四行是 **Other**：

| Figure 3 的 Other subgroup | Levosimendan | Placebo |
|---|---:|---:|
| Successful ECMO weaning | 15/21（71.4%） | 12/21（57.1%） |
| 合并报告的 treatment effect | **sHR 1.61；95% CI 0.78–3.33** | |

位置：[正文第 7 页，期刊页 66，Figure 3][main7]。补充 eFigure 9 的 panel D 标题是 **Others**，重复报告相同 sHR 和 95% CI，未另外展示 post-cardiac-arrest panel。[补充材料第 18 页，eFigure 9][results18]

**5．Other 究竟包含哪些患者：原文及人数核对**

Figure 3 脚注 a 的完整原文：

> Other causes of cardiogenic shock (eTable 6 in Supplement 3) included cardiac arrest prior to ECMO initiation, acute cardiac arrhythmia, Takotsubo cardiomyopathy, decompensated dilated cardiomyopathy, acute valvular disease, and miscellaneous conditions such as sepsis, late complications of congenital heart disease, and thyrotoxic cardiomyopathy.

中文译文：

> 心源性休克的其他原因〔见 Supplement 3 的 eTable 6〕包括：ECMO 启动前发生心脏骤停、急性心律失常、Takotsubo 心肌病、失代偿性扩张型心肌病、急性瓣膜病，以及脓毒症、先天性心脏病晚期并发症和甲状腺毒症性心肌病等其他情况。

位置：[正文第 7 页，Figure 3 脚注 a][main7]。

我直接查看 eTable 6，并逐项重新加总：

| eTable 6 原始类别及中文 | Levosimendan | Placebo |
|---|---:|---:|
| Decompensated dilated cardiomyopathy／失代偿性扩张型心肌病 | 3 | 9 |
| Acute cardiac arrhythmia／急性心律失常 | 6 | 6 |
| **Cardiac arrest prior to ECMO／ECMO 前心脏骤停** | **5** | **1** |
| Takotsubo cardiomyopathy／Takotsubo 心肌病 | 3 | 1 |
| Acute valvular disease／急性瓣膜病 | 1 | 3 |
| Miscellaneous conditions／其他情况 | 3 | 1 |
| **合计** | **21** | **21** |

位置：[补充材料第 9 页，eTable 6][results9]。

可以直接确认：

- Other 共 **42 人**；
- 其中以 “Cardiac arrest prior to ECMO” 分类的共 **6 人**；
- 其余 **36 人**分属其他诊断类别。

**因此，Other 的 sHR 不能直接归属于单独的 post-cardiac-arrest subgroup。**

同时，eTable 6 不能回答其他病因类别中是否也有患者经历过 cardiac arrest，也不能独立确定 protocol 中 planned post-cardiac-arrest subgroup 的完整 operational definition。将它简化成“计划 subgroup 必定恰好只有 6 人”，会超出这些来源能直接支持的范围。

**6．对 downstream analysis 的影响**

C006 的 `Review_domain` 是 `protocol_report`。它直接涉及 subgroup population 与 treatment effect 的归属，因而有以下统计解释和证据提取影响。

**第一，post-cardiac-arrest 专题的 systematic review 无法从该 Other estimate 提取对应 treatment effect。**若将 sHR 1.61（95% CI 0.78–3.33）编码为 post-cardiac-arrest-specific estimate，就会把整个混合 Other subgroup 的结果归到其中一种诊断。该 estimate 应保留其原始 population label 和组成说明。

**第二，现有汇总人数不足以重建所缺少的 subgroup estimate。**15/21 与 12/21 没有说明 cardiac-arrest 类别中各有多少 successful weaning，更没有给出对应 event times、censoring 或 competing events。无法将 Other 的 sHR 按 6/42 缩放，也无法从整个 Other 的结果中直接分离出 post-cardiac-arrest sHR。

**第三，报告的 interaction 结论具有明确的 subgroup scheme 边界。**正文的完整 Subgroup Analyses 段落是：

> There was no statistically significant heterogeneity of treatment effect between the 2 study groups across any of the prespecified subgroups (Figure 3; eFigure 9 in Supplement 3).

中文译文：

> 在所报告的 prespecified subgroups 中，两 study groups 之间的 treatment effect 未呈现 statistically significant heterogeneity，相关结果见 Figure 3 和 Supplement 3 的 eFigure 9。

位置：[正文第 7 页，左栏 Subgroup Analyses][main7]。

Figure 3 的 **P value for interaction＝.74** 对应图中展示的 etiology subgroup factor。它没有提供单独的 cardiac-arrest interaction test；“未见 statistically significant heterogeneity”也不能证明所有具体诊断类别的 treatment effect 相同。

**第四，prespecified status 的依据尚未完整对接。**报告将 Other analysis 称为 predefined／prespecified；所提供 protocol 的明确 outcome subgroup 列表写的是 post-cardiac arrest。Other 已用于 minimization 和 adjustment，这一点应予保留。若另有详细 analysis plan 或 amendment 将其指定为 analytic subgroup，则可能解释当前差异；本次所提供材料中未找到该文件。

我本次独立确认的是 **population 与 prespecification 的报告差异**。现有证据不能确定改变 subgroup 的原因，不能认定存在结果驱动的选择，也不能判断单独报告 planned subgroup 后主要结论是否会变化。仍待补齐的是支持 Other analysis 的相应文件，以及 planned post-cardiac-arrest subgroup 的 operational definition 和单独结果。[本次独立核对记录](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/c006_followup_20261020/independent_source_check.txt)

[protocol106]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=106
[protocol107]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=107
[sap6]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=6
[main4]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=4
[main7]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=7
[results9]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=9
[results18]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=18

---

## 12. User

continue on C005

---

## 13. Assistant — Progress update

我会继续核对 C005 的审查经过和原始 PDF，按您刚才的要求提供关键段落原文、中文译文及来源位置，并保留 statistical terminology 的英文。

---

## 14. Assistant — Progress update

C005 的现有记录涉及 MACE 的 component definition：protocol 和正文列入 dialysis，SAP 及补充图的定义未列入。我会直接核对这些列表及其对应的 D30／D60 结果，区分定义差异与人数对照能支持的结论。本次页面渲染使用 CPU。

---

## 15. Assistant — Progress update

原始 PDF 确认了两套 MACE component list；eFigure 4 的 D30／D60 最终 event counts 也与 eTable 3 一致。还需要保留一个人数对照：安慰剂组 D30 dialysis 为 38 人，MACE 为 36 人。若两行采用相同 population、time window 和 dialysis 定义，且 MACE 包含 dialysis，就需要解释这一关系；目前材料不足以确定实际采用的 composite coding。

---

## 16. Assistant — Answer

**C005 涉及 MACE 的 component definition：protocol 和正文明确包含 dialysis；SAP 的两处定义及补充 eFigure 4 则未列入 dialysis。**我重新查看原始 PDF 后，确认这些 component lists 确实不同。

目前能确认的是**报告中的定义差异**。实际计算 D30／D60 MACE 时是否包含 dialysis，仍无法从现有汇总结果确定。以下提供原文、中文译文和来源位置，statistical terminology 保留英文。

**1．C005 在审查中经历了什么**

跨文件检查提出 `F-XS-002`，第一轮 statistical review 独立提出 `F-ST1-003`。两项经 independent inclusion screening 后，合并为 C005；后续 source recheck 和 quality audit 均保留该候选项。

| 字段 | 当前记录 |
|---|---|
| `Review_domain` | `protocol_report` |
| `Relationship type` | `P_R` |
| `All relationships` | `P_R, P_P, S_C` |
| `Evidence state` | `reproduced` |
| `Inclusion audit` | `CONFIRMED` |
| 状态 | `Pending Human Adjudication` |

这里保留三种 relationships，是因为差异同时存在于 protocol 与 SAP、正文与补充材料，以及 PLAN 与 REPORT 之间。按照审查规则，`P_R` 优先，因而归入 `protocol_report`。[C005 审查卡](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/final_report_1_6_2.md:297)

本次我重新提取原始文本，并直接查看 protocol、SAP、正文、eTable 3 和 eFigure 4 的关键页面。六份来源 PDF 的 SHA-256 均与原审查记录一致。下面页码均指 **PDF 页码**。

**2．protocol 和正文如何定义 MACE**

最终版 protocol，version 3.0，§4.1.2 的相关完整条目为：

> Major adverse cardiovascular events defined as death, cardiac transplant, escalation to permanent left ventricular assist device, stroke, dialysis, re-hospitalization for heart failure on days 30 and 60

中文译文：

> 第 30 天和第 60 天的 MACE 定义为：死亡、心脏移植、升级至永久性左心室辅助装置、卒中、透析，以及因心力衰竭再次住院。

位置：[protocol 第 106 页，印刷页 13/46，§4.1.2][protocol106]。

我也核对了第 8、14、15、53、59、60、99、105 页的重复定义，均列有 dialysis。

正文 Outcomes 的相关**完整段落**如下：

> Predefined secondary outcomes included all-cause mortality at 30 days and 60 days; days alive without organ failure at day 30 (SOFA score 0-1 for each component); durations of ECMO and mechanical ventilation and ECMO- and ventilation-free days at 30 and 60 days (death counted as 0 days); duration of catecholamine support and days alive without it at day 30; duration of kidney replacement therapy and days alive without it at day 30; left ventricular ejection fraction by echocardiography at day 30; major adverse cardiovascular events (death, heart transplant, escalation to need for left ventricular assist device, stroke, dialysis, or heart failure rehospitalization) at days 30 and 60; and ICU and hospital lengths of stay. Time to hemodynamic improvement (mean blood pressure >60 mm Hg) was planned but not analyzed, as most patients remained stable; mean blood pressure evolution was instead evaluated graphically up to day 30.

中文译文：

> Predefined secondary outcomes 包括：第 30 天及第 60 天的全因死亡；第 30 天存活且无器官衰竭的天数〔每个 SOFA component 为 0–1〕；ECMO 和机械通气持续时间，以及第 30 天和第 60 天的 ECMO-free days、ventilation-free days〔死亡者计为 0 天〕；儿茶酚胺支持持续时间及第 30 天存活且无需此类支持的天数；肾脏替代治疗持续时间及第 30 天存活且无需此类治疗的天数；第 30 天通过超声心动图测得的左心室射血分数；第 30 天和第 60 天的 MACE〔死亡、心脏移植、升级至需要左心室辅助装置、卒中、透析，或因心力衰竭再次住院〕；以及 ICU 和住院时长。原计划分析达到血流动力学改善〔mean blood pressure＞60 mm Hg〕所需时间，但由于多数患者保持稳定，未进行该项分析，改为用图形展示截至第 30 天的 mean blood pressure 变化。

位置：[正文第 3 页，期刊页 62，右栏 Outcomes 续段][main3]。

因此，**正文延续了包含 dialysis 的六项 component list**。

**3．SAP 和补充图如何定义 MACE**

SAP §3.6 中，MACE 的**完整段落**为：

> Major Adverse Cardiovascular Events (MACE): MACE is defined as the occurrence of any of the following events on days 30 and 60: death, cardiac transplant, escalation to a permanent left ventricular assist device, stroke, or re-hospitalization for heart failure. The incidence of MACE will be described using survival analysis with Kaplan-Meier estimation and 95% confidence interval. Only survival analysis up to 60 days will be performed. In this analysis, time will be defined as the time from the date of randomization to the date of MACE occurrence, the date of the last follow-up update, or the end of follow-up, whichever comes first. Differences between groups will be assessed using the log-rank test. To adjust for the primary etiology of cardiogenic shock, a Cox proportional hazards model will be employed.

中文译文：

> MACE 定义为在第 30 天和第 60 天发生以下任一事件：死亡、心脏移植、升级至永久性左心室辅助装置、卒中，或因心力衰竭再次住院。MACE incidence 将通过 survival analysis，采用 Kaplan-Meier estimation 和 95% confidence interval 描述。仅开展截至第 60 天的 survival analysis。在该 analysis 中，time 定义为 randomization 日期至 MACE 发生日期、最后一次随访更新日期或随访结束日期的间隔，以最先发生者为准。组间差异采用 log-rank test 评估。为对心源性休克主要病因进行 adjustment，将采用 Cox proportional hazards model。

位置：[SAP 第 7 页，§3.6，MACE 段落][sap7]。

这段只列出五项，没有 dialysis。SAP 第 4 页 §2.2 的 endpoint definition 也给出相同五项列表：

> Major Adverse Cardiovascular Events (MACE): Defined as the occurrence, on days 30 and 60, of any of the following: death, cardiac transplant, escalation to a permanent left ventricular assist device, stroke, or re-hospitalization for heart failure.

中文译文：

> MACE 定义为在第 30 天和第 60 天发生以下任一事件：死亡、心脏移植、升级至永久性左心室辅助装置、卒中，或因心力衰竭再次住院。

位置：[SAP 第 4 页，§2.2][sap4]。

补充 eFigure 4 的完整标题为：

> eFigure 4. D30 and D60 Cumulative Incidence of Major Cardiac Adverse Events (MACE) Defined as Death, Cardiac Transplant, Escalation to Permanent Left Ventricular Assist Device, Stroke, or Re-Hospitalization for Heart Failure

中文译文：

> eFigure 4：D30 和 D60 的 MACE Cumulative Incidence；MACE 定义为死亡、心脏移植、升级至永久性左心室辅助装置、卒中，或因心力衰竭再次住院。

位置：[补充材料第 13 页，eFigure 4][results13]；同一标题还出现在[第 1 页目录][results1]。

逐项对照后，差异很集中：

| Component | Protocol／正文 | SAP／eFigure 4 |
|---|---|---|
| Death | 列入 | 列入 |
| Cardiac transplant | 列入 | 列入 |
| LVAD escalation | 列入 | 列入 |
| Stroke | 列入 | 列入 |
| **Dialysis** | **列入** | **未列入** |
| Heart-failure rehospitalization | 列入 | 列入 |

**这正是 C005 被保留的依据：同一 MACE 标签对应了不同的 composite definition。**

**4．实际报告的结果是什么**

我重新查看 eTable 3，并核对了 eFigure 4 的最终 cumulative number of events：

| 结果 | Levosimendan | Placebo | 报告的 RR（95% CI） |
|---|---:|---:|---|
| D30 MACE | 35/101（34.7%） | 36/104（34.6%） | 1.00（0.69–1.46） |
| D60 MACE | 36/101（35.6%） | 39/104（37.5%） | 0.95（0.66–1.36） |
| D30 dialysis | 29/101（28.7%） | 38/104（36.5%） | 0.79（0.53–1.17） |
| D60 dialysis | — | — | 未提供 |

位置：[补充材料第 5 页，eTable 3 的 D30 部分][results5]；[第 6 页，D60 部分][results6]。D60 dialysis 的横线不能解释为 0。

eFigure 4 的最终 event counts 与表格一致：D30 为 35／36，D60 为 36／39；图上 log-rank P values 分别为 .87 和 .94。[eFigure 4][results13]

我另外核算：

\[
RR_{D30}=\frac{35/101}{36/104}=1.0011\approx1.00
\]

\[
RR_{D60}=\frac{36/101}{39/104}=0.9505\approx0.95
\]

这些核算支持表内 RR 与所列人数相符，**但不能判断这些人数对应五项还是六项 composite**。表与图重复相同人数，也不能单独确定其实际 component coding。

**5．如何理解“dialysis 38 人、MACE 36 人”**

安慰剂组 D30 的这一对照值得保留：

- dialysis：38 人；
- MACE：36 人。

如果两行使用相同 population、time window 和 dialysis coding，而且 dialysis 确实属于 MACE，那么必须满足：

\[
N(\text{MACE})\geq N(\text{dialysis})
\]

在这些条件下，36 与 38 不满足这一包含关系。**其他 components 之间存在 overlap，也不能使 composite union 小于其中单个 component。**

此前审查没有把它另列为独立 numeric candidate：按照该 workflow 的 display-precision rule，对 `[37.5,38.5]` 与 `[35.5,36.5]` 计算得到 gap＝1、relative discrepancy＝1/36≈0.0278，未超过 0.05 阈值。[相关审查规则](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/QUALITY_CONTROL_SCOPE.md:130)

这里要区分：**这是该 workflow 的 screening convention，并不证明 exact integer counts 的包含关系可由 rounding 调和。**C005 的独立依据仍是原文明确列出的 composite components 不同；38／36 的对照也不足以单独证明作者实际采用了哪一套定义。

**6．对 downstream analysis 的影响**

C005 的 `Review_domain` 是 `protocol_report`，同时直接影响 MACE 结果的解释与提取。

**第一，systematic review 可能给结果附上不同的 endpoint definition。**例如，按正文提取六项定义，却引用按五项定义计算的 RR，就会造成 definition 与 estimate 的归属不一致。当前材料尚不能确认实际发生了哪一种情况；能够确认的是，提取者面临两套明确的定义。

**第二，不能通过加上或减去 dialysis 人数来重建另一套 composite。**设：

- \(A\)：在指定时点前发生五项共有 components 中至少一项的患者；
- \(D\)：在同一条件下发生 dialysis 的患者。

那么：

\[
N_{\text{six-component}}=|A\cup D|
=|A|+|D\setminus A|
\]

需要知道的是 **dialysis-only 患者数**。汇总表没有提供患者之间的 component overlap，因此不能直接把 29 或 38 加到 MACE 人数上，也不能据此计算另一套 RR 或 95% CI。

**第三，time-to-first-event analysis 还取决于 event dates。**即使一名患者已因另一 component 被计入 MACE，若其 dialysis 更早发生，加入 dialysis 仍可能提前该患者的 first-event time。因此，final event counts 相同，也不足以证明 survival curves、log-rank test 或 Cox model 结果相同。

**第四，目前无法量化结论会怎样变化。**两组 dialysis 人数不同，并不能确定加入或移除 dialysis 后 treatment effect 的方向或大小；这还取决于 overlap、event dates 和实际 coding。现有资料不支持推断 RR 会跨过 1、P value 会改变判断，或主要结论会变化。

我本次确认了 C005 的来源依据，并保留两种可能解释：实际采用五项 composite，而 protocol／正文保留了 dialysis；或实际采用六项 composite，而 SAP／图中列表省略了 dialysis。**要确定哪一种成立，仍需明确说明：D30／D60 MACE 的 counts、RR 和 curves 是否包含 dialysis，以及对应的 component coding、time window 和修订依据。**[本次独立来源核对记录](/home/bulun-debian/ai-paper-val/2025/jama.2025.19843/.ai_paper_validation/review_1_6_2/c005_followup_20261020/independent_source_check.txt)

[protocol106]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp1_prod_1766516490.96011.pdf#page=106
[main3]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/jama_combes_2025_oi_250087_1766516490.94011.pdf#page=3
[sap4]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=4
[sap7]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp2_prod_1766516490.96511.pdf#page=7
[results1]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=1
[results5]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=5
[results6]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=6
[results13]: /home/bulun-debian/ai-paper-val/2025/jama.2025.19843/joi250087supp3_prod_1766516490.97011.pdf#page=13

---

## 17. User

save the conversation into a md file and put it inside the subfolder ./review_records/*

---

## 18. Assistant — Progress update

I’ll save the user messages and assistant responses from this conversation to a Markdown file in `./review_records/`.
